Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Liposomal Doxorubicin

Liposomal Doxorubicin anthracycline doxorubicin by reducing the drug’s cardiotoxicity, but maintaining its antitumor efficacy. Liposomal doxorubicin plus cyclophosphamide is no less effective than conventional doxorubicin or epirubicin plus cyclophosphamide in the first-line treatment of women with metastatic breast cancer. In addition, the drug is significantly less cardiotoxic than conventional doxorubicin. The median cumulative dose to the first cardiac event for liposomal doxorubicin is higher than that for conventional doxorubicin; the potential to use dox- orubicin for a longer period of time may benefit a number of patients. Liposomal doxorubicin has also shown potential as part of a chemotherapy regimen in patients with non-Hodgkin lymphoma (NHL). Thus, liposomal doxorubicin represents an important advance in terms of offering reduced cardiotoxicity compared with conventional doxorubicin, and can be used in preference to conventional doxorubicin in a combination regimen with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. The rationale used as the basis for the design of intravenous liposomal doxorubicin is that the liposomes cannot Pharmacologic exit the circulation in healthy tissues, but can exit through leaky tumor-associated vessels. In animal models, Properties liposomal doxorubicin is less cardiotoxic than conventional doxorubicin, and reduces mammary tumor growth to a significantly greater extent http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Loading next page...
 
/lp/springer-journals/liposomal-doxorubicin-g7x5i2624T
Publisher
Springer Journals
Copyright
Copyright © 2005 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200504030-00006
Publisher site
See Article on Publisher Site

Abstract

anthracycline doxorubicin by reducing the drug’s cardiotoxicity, but maintaining its antitumor efficacy. Liposomal doxorubicin plus cyclophosphamide is no less effective than conventional doxorubicin or epirubicin plus cyclophosphamide in the first-line treatment of women with metastatic breast cancer. In addition, the drug is significantly less cardiotoxic than conventional doxorubicin. The median cumulative dose to the first cardiac event for liposomal doxorubicin is higher than that for conventional doxorubicin; the potential to use dox- orubicin for a longer period of time may benefit a number of patients. Liposomal doxorubicin has also shown potential as part of a chemotherapy regimen in patients with non-Hodgkin lymphoma (NHL). Thus, liposomal doxorubicin represents an important advance in terms of offering reduced cardiotoxicity compared with conventional doxorubicin, and can be used in preference to conventional doxorubicin in a combination regimen with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. The rationale used as the basis for the design of intravenous liposomal doxorubicin is that the liposomes cannot Pharmacologic exit the circulation in healthy tissues, but can exit through leaky tumor-associated vessels. In animal models, Properties liposomal doxorubicin is less cardiotoxic than conventional doxorubicin, and reduces mammary tumor growth to a significantly greater extent

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References